证券代码：603122 证券简称：合富中国 公告编号：临 2025-032 重要内容提示： 业绩预告的具体适用情形：净利润为负值。 经财务部门初步测算，合富（中国）医疗科技股份有限公司（以下简称 "公司"）预计 2025 年半年度归属于母公司所有者的净利润为-900 万元到-630 万元，与上年同期（法定披露数据）相比，将出现亏损。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 合富（中国）医疗科技股份有限公司 2025 年半年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 三、本期业绩预亏的主要原因 1、2025 年上半年度内，受国内宏观环境变化及集中采购降价等医疗政策环 境影响，公司医院客户的产品采购价格调低，订单采购量不及上年同期，导致公 司销售收入及毛利出现同步下降。 2、为应对市场及业务变化，公司积极调整业务布局和发展策略，持续集中 及扩大资源投入"ACME"自有产品迭代研发及生产，扩增市场开发队伍，提升对 医院客户高附加值 ...

合富（中国）医疗科技股份有限公司董事会 2025 年 7 月 11 日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买 卖中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收 入数据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海 证券交易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司 营业收入。本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据 以公司定期报告为准，敬请投资者注意投资风险。 公司 2025 年 1-6 月合并营业收入人民币 36,765.82 万元，较去年同期下降 23.53%，2025 年 1-5 月合并营业收入较去年同期下降 24.15%，下降幅度收窄 0.62%，营收情况持续改善。 特此公告。 证券代码：60312 ...

合富中国：2025年1-6月累计营业收入3.68亿元，同比下降23.53% 金十数据7月10日讯，合富中国公告，2025年1-6月公司合并营业收入为3.68亿元，较去年同期下降 23.53%，2025年1-5月同比下降24.15%，降幅收窄0.62%，营收情况持续改善。 ...

Core Points - The stock price of HeFu China (603122) increased by 2.07% to 6.89 CNY as of July 4, 2025, with a market capitalization of 2.743 billion CNY [1] - The company completed the cancellation of its initial public offering (IPO) fundraising account, with a total fundraising amount of 416.96 million CNY and a net amount of 359.69 million CNY after expenses [1][2] - HeFu China announced a cash dividend of 0.13 CNY per share for the 2024 annual equity distribution, totaling 51.75 million CNY [3] Company Announcements - HeFu China has completed the cancellation of its IPO fundraising account, with the balance of 58.45 million CNY transferred to the general account [2] - The company signed a tripartite supervision agreement regarding the fundraising account and later terminated it after the account's cancellation [2] - The cash dividend distribution was approved at the annual shareholders' meeting on June 25, 2025, with specific tax implications for different types of shareholders [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会《关于核准合富（中国）医疗科技股份有限公 司首次公开发行股票的批复》（证监许可〔2021〕4074 号）核准，合富（中国） 医疗科技股份有限公司（以下简称"公司"）首次向社会公开发行人民币普通股 证券代码：603122 证券简称：合富中国 公告编号：临 2025-030 合富（中国）医疗科技股份有限公司 关于募集资金专户完成销户的公告 ），并使用部分募集资金向合益信息提供借款以 实施募投项目，公司于 2022 年 6 月与全资子公司合益信息、保荐机构海通证券 股份有限公司、存放募集资金的富邦华一银行有限公司上海徐汇支行签署了《募 集资金专户存储四方监管协议》（以下简称"四方监管协议"）。三方监管协议、 四方监管协议明确了各方的权利和义务，与上海证券交易所《募集资金专户存储 三方监管协议（范本）》不存在重大差异，公司在使用募集资金时已经严格遵照 履行。 为提高募集资金收益率，公司于 2024 年 6 月 19 日召开第二届董事会第十一 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-029 合富（中国）医疗科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.13元 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/11 | － | 2025/7/14 | 2025/7/14 | 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 6 月 25 日的2024年年度股东会审议通过。 本次利润分配以方案实施前的公司总股本398,052,633股为基数，每股派发现金红利0.13 元（含税），共计 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-030 合富（中国）医疗科技股份有限公司 关于募集资金专户完成销户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司本次注销的募集资金专户信息如下： 二、募集资金存放和管理情况 为规范公司募集资金管理和使用，保护投资者权益，按照《中华人民共和国 公司法》《中华人民共和国证券法》《上海证券交易所股票上市规则》《上市公司 监管指引第 2 号——上市公司募集资金管理和使用的监管要求》和《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》等有关法律、法规和规范性文 件的规定，结合公司实际情况，公司已制定了《募集资金管理制度》，对募集资 金实行专户存储制度，对募集资金的存放、使用、项目实施管理、投资项目的变 更及使用情况的监督进行了规定。公司于 2022 年 2 月与保荐机构海通证券股份 有限公司、存放募集资金的上海银行虹桥路支行、兴业银行股份有限公司上海分 1 行营业部、富邦华一银行有限公司上海徐汇支行、招商银行股份有限公司上海分 行营业部分别签署 ...

Group 1 - The first meeting of the third board of directors of Hefei (China) Medical Technology Co., Ltd. was held on June 25, 2025, with all six directors present, and the meeting was conducted legally and effectively [1] - Li Jun was elected as the chairman of the third board of directors, with a term lasting until the end of the current board's term [1][2] - The board approved the election of various specialized committees, with Li Jun serving as the chairman of the Strategy and ESG Committee [2] Group 2 - Wang Qiongzhi was appointed as the general manager, with a term lasting until the end of the current board's term [3] - The board also appointed Zeng Guankai, Wang Fenghua, and Chen Ye as vice general managers, and Wang Qiongzhi as the financial supervisor [3][4] - Zhu Ying was appointed as the board secretary, and Xu Jiayuan was appointed as the securities affairs representative, both with terms until the end of the current board's term [3][4]

Core Viewpoint - The legal opinion letter issued by Beijing Global Law Firm Shanghai Branch confirms that the 2024 Annual General Meeting of Shareholders of HeFu (China) Medical Technology Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legality and validity of the meeting procedures and voting results [1][3][22]. Group 1: Meeting Procedures - The annual general meeting was held on June 25, 2025, with the notice published on June 5, 2025, meeting the requirement of a 20-day advance notice [3][5]. - The meeting was conducted at the specified location, and both on-site and online voting options were provided to shareholders [5][6]. Group 2: Qualifications of Participants - The second board of directors of HeFu China convened a meeting on June 4, 2025, to propose the annual general meeting, confirming the board as the convener [5][6]. - A total of 3 shareholders and their proxies attended the meeting, representing 792,224 shares, which is 0.1990% of the total voting shares [5][6]. Group 3: Proposals and Voting Procedures - No additional proposals were made beyond those listed in the meeting notice, and all proposals were voted on as stated [6][22]. - The voting process combined both on-site and online methods, with shareholders required to choose one voting method [7][22]. Group 4: Voting Results - The voting results for various proposals showed overwhelming support, with the majority receiving over 99% approval [8][9][10][11][12][13][14][15][16][17][18][19][20][21]. - Specific proposals included the annual board work report, independent director's report, and financial statements, all of which received high approval rates [8][9][10][11][12][19].

Meeting Overview - The annual general meeting of the company was held on June 25, 2025, at the Guangqi Building, Shanghai [1] - The meeting was conducted in compliance with the Company Law of the People's Republic of China and the company's articles of association [1] Attendance and Voting - The meeting was attended by shareholders representing a significant majority of the voting rights, with various voting methods including on-site and online participation [1] - The voting results showed a high level of agreement among shareholders, with most resolutions passing with over 99% approval [1][2][3] Resolutions Passed - Multiple resolutions were approved, including those related to the election of directors and the authorization for changes in business registration [1][2][3] - Specific voting results included: - 224,829,664 votes in favor (99.7408%) for one resolution [1] - 224,805,364 votes in favor (99.7300%) for another resolution [1] - 224,830,564 votes in favor (99.7412%) for yet another resolution [1] Legal Compliance - The meeting's procedures and resolutions were confirmed to be legally valid by the attending lawyers, ensuring compliance with relevant laws and regulations [7][9]